HCW Biologics Financials
| HCWB Stock | USD 0.61 0.16 20.78% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.49 | 0.4683 |
|
| |||||
| Current Ratio | 0.7 | 0.7321 |
|
|
The financial analysis of HCW Biologics is a critical element in measuring its lifeblood. Investors should not minimize HCW Biologics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
HCW | Select Account or Indicator |
Understanding current and past HCW Biologics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of HCW Biologics' financial statements are interrelated, with each one affecting the others. For example, an increase in HCW Biologics' assets may result in an increase in income on the income statement.
Please note, the presentation of HCW Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, HCW Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of HCW Biologics' management manipulating its earnings.
HCW Biologics Stock Summary
HCW Biologics competes with Anebulo Pharmaceuticals, Rezolute, Eliem Therapeutics, Molecular Partners, and MediciNova. HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company was incorporated in 2018 and is headquartered in Miramar, Florida. Hcw Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US40423R1059 |
| CUSIP | 40423R105 |
| Location | Florida; U.S.A |
| Business Address | 2929 North Commerce |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.hcwbiologics.com |
| Phone | 954 842 2024 |
| Currency | USD - US Dollar |
HCW Biologics Key Financial Ratios
| Return On Equity | -3.44 | ||||
| Operating Margin | (22.36) % | ||||
| Price To Sales | 8.24 X | ||||
| Revenue | 2.84 M | ||||
| Gross Profit | 4.1 M |
HCW Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HCW Biologics's current stock value. Our valuation model uses many indicators to compare HCW Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HCW Biologics competition to find correlations between indicators driving HCW Biologics's intrinsic value. More Info.HCW Biologics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, HCW Biologics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HCW Biologics' earnings, one of the primary drivers of an investment's value.HCW Biologics Systematic Risk
HCW Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. HCW Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on HCW Biologics correlated with the market. If Beta is less than 0 HCW Biologics generally moves in the opposite direction as compared to the market. If HCW Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one HCW Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of HCW Biologics is generally in the same direction as the market. If Beta > 1 HCW Biologics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in HCW Biologics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various HCW Biologics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of HCW Biologics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
HCW Biologics November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of HCW Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of HCW Biologics. We use our internally-developed statistical techniques to arrive at the intrinsic value of HCW Biologics based on widely used predictive technical indicators. In general, we focus on analyzing HCW Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build HCW Biologics's daily price indicators and compare them against related drivers.
| Downside Deviation | 9.54 | |||
| Information Ratio | 0.0961 | |||
| Maximum Drawdown | 352.85 | |||
| Value At Risk | (13.64) | |||
| Potential Upside | 22.0 |
Complementary Tools for HCW Stock analysis
When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |